Literature DB >> 30891617

Innate immune regulatory networks in hepatic lipid metabolism.

Lan Bai1,2, Hongliang Li3,4,5,6,7.   

Abstract

Hepatic lipid metabolism is closely associated with certain diseases, such as obesity, diabetes, fatty liver, and hepatic fibrosis. Hepatic steatosis results from systemic metabolic dysfunction that occurs via multiple processes. The initial process has been characterized as hepatic lipid accumulation that may be caused by increased liver lipid uptake and de novo lipogenesis or decreased lipid oxidation and lipid export; subsequently, multiple additional factors that trigger inflammation and insulin resistance (IR) aggravate the progression of hepatic steatosis. Emerging evidence indicates that inflammation stands at the crossroads of innate immunity and lipid metabolism and links the initial metabolic stress and subsequent metabolic events in lipid metabolism. Therefore, in this review, we summarize the regulatory role of innate immune signaling molecules in maintaining lipid metabolic homeostasis; these revelations can guide the development of potential therapies for nonalcoholic fatty liver disease (NAFLD).

Entities:  

Keywords:  Inflammation; Innate immunity; Insulin resistance; Lipid metabolism; NAFLD

Mesh:

Year:  2019        PMID: 30891617     DOI: 10.1007/s00109-019-01765-1

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  85 in total

Review 1.  Pattern recognition receptors and inflammation.

Authors:  Osamu Takeuchi; Shizuo Akira
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice.

Authors:  Kouichi Miura; Yuzo Kodama; Sayaka Inokuchi; Bernd Schnabl; Tomonori Aoyama; Hirohide Ohnishi; Jerrold M Olefsky; David A Brenner; Ekihiro Seki
Journal:  Gastroenterology       Date:  2010-03-27       Impact factor: 22.682

3.  JNK1 but not JNK2 promotes the development of steatohepatitis in mice.

Authors:  Jörn M Schattenberg; Rajat Singh; Yongjun Wang; Jay H Lefkowitch; Raina M Rigoli; Philipp E Scherer; Mark J Czaja
Journal:  Hepatology       Date:  2006-01       Impact factor: 17.425

Review 4.  Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites.

Authors:  Brent A Neuschwander-Tetri
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

Review 5.  The defensive alliance between neutrophils and NK cells as a novel arm of innate immunity.

Authors:  Claudio Costantini; Marco A Cassatella
Journal:  J Leukoc Biol       Date:  2010-08-03       Impact factor: 4.962

6.  Toll-like receptor 2 deficiency improves insulin sensitivity and hepatic insulin signalling in the mouse.

Authors:  L-H Kuo; P-J Tsai; M-J Jiang; Y-L Chuang; L Yu; K-T A Lai; Y-S Tsai
Journal:  Diabetologia       Date:  2010-10-22       Impact factor: 10.122

Review 7.  [Recognition of pathogens by innate immunity].

Authors:  Marta Sochocka
Journal:  Postepy Hig Med Dosw (Online)       Date:  2008-12-11       Impact factor: 0.270

8.  Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition.

Authors:  Eiichiro Yamamoto; Yi-Fei Dong; Keiichiro Kataoka; Takuro Yamashita; Yoshiko Tokutomi; Shinji Matsuba; Hidenori Ichijo; Hisao Ogawa; Shokei Kim-Mitsuyama
Journal:  Hypertension       Date:  2008-08-04       Impact factor: 10.190

9.  Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease.

Authors:  Puneet Puri; Faridoddin Mirshahi; Onpan Cheung; Ramesh Natarajan; James W Maher; John M Kellum; Arun J Sanyal
Journal:  Gastroenterology       Date:  2007-10-26       Impact factor: 22.682

10.  Nuclear orphan receptor TAK1/TR4-deficient mice are protected against obesity-linked inflammation, hepatic steatosis, and insulin resistance.

Authors:  Hong Soon Kang; Kyoko Okamoto; Yong-Sik Kim; Yukimasa Takeda; Carl D Bortner; Huaixin Dang; Taira Wada; Wen Xie; Xiao-Ping Yang; Grace Liao; Anton M Jetten
Journal:  Diabetes       Date:  2010-09-23       Impact factor: 9.461

View more
  16 in total

Review 1.  Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management.

Authors:  Alexandra Jichitu; Simona Bungau; Ana Maria Alexandra Stanescu; Cosmin Mihai Vesa; Mirela Marioara Toma; Cristiana Bustea; Stela Iurciuc; Marius Rus; Nicolae Bacalbasa; Camelia Cristina Diaconu
Journal:  Diagnostics (Basel)       Date:  2021-04-12

Review 2.  Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application.

Authors:  Yu Xu; Wei Guo; Cheng Zhang; Feiyu Chen; Hor Yue Tan; Sha Li; Ning Wang; Yibin Feng
Journal:  Front Pharmacol       Date:  2020-05-12       Impact factor: 5.810

Review 3.  Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk.

Authors:  Agostino Di Ciaula; Jacek Baj; Gabriella Garruti; Giuseppe Celano; Maria De Angelis; Helen H Wang; Domenica Maria Di Palo; Leonilde Bonfrate; David Q-H Wang; Piero Portincasa
Journal:  J Clin Med       Date:  2020-08-14       Impact factor: 4.241

4.  Biochanin A Regulates Cholesterol Metabolism Further Delays the Progression of Nonalcoholic Fatty Liver Disease.

Authors:  Yan Fan; Long-Teng Yan; Zheng Yao; Guang-Yi Xiong
Journal:  Diabetes Metab Syndr Obes       Date:  2021-07-09       Impact factor: 3.168

Review 5.  Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?

Authors:  Agostino Di Ciaula; Salvatore Passarella; Harshitha Shanmugam; Marica Noviello; Leonilde Bonfrate; David Q-H Wang; Piero Portincasa
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

Review 6.  Nonalcoholic fatty liver disease and COVID-19: An epidemic that begets pandemic.

Authors:  Musaab Ahmed; Mohamed H Ahmed
Journal:  World J Clin Cases       Date:  2021-06-16       Impact factor: 1.337

Review 7.  Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Ignazio Grattagliano; Agostino Di Ciaula; Jacek Baj; Emilio Molina-Molina; Harshitha Shanmugam; Gabriella Garruti; David Q-H Wang; Piero Portincasa
Journal:  Methods Mol Biol       Date:  2021

Review 8.  COVID-19 and non-alcoholic fatty liver disease: Two intersecting pandemics.

Authors:  Piero Portincasa; Marcin Krawczyk; Wiktor Smyk; Frank Lammert; Agostino Di Ciaula
Journal:  Eur J Clin Invest       Date:  2020-08-26       Impact factor: 5.722

9.  Herbal formulation MIT ameliorates high-fat diet-induced non-alcoholic fatty liver disease.

Authors:  Sang-Hyun Ahn; Eun-Sun Yang; Hey-Rin Cho; Syng-Ook Lee; Ki-Tae Ha; Kibong Kim
Journal:  Integr Med Res       Date:  2020-05-14

10.  Tanshinone IIA ameliorates non-alcoholic fatty liver disease through targeting peroxisome proliferator-activated receptor gamma and toll-like receptor 4.

Authors:  Lu Huang; Wei Ding; Ming-Qiang Wang; Zheng-Gen Wang; Hong-Hui Chen; Wen Chen; Qiong Yang; Ting-Na Lu; Qing Yang; Ji-Man He
Journal:  J Int Med Res       Date:  2019-08-05       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.